On June 11, 2020, VIELA BIO announced the receipt of FDA approval for a novel therapeutic, signaling the company's expansion into a new pipeline area and strengthening its portfolio of innovative treatments. The approval sets the stage for a potential revenue run-rate and disruptability within the emerging market segment, driving significant near-term investor attention.